117 related articles for article (PubMed ID: 17484832)
21. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Schneider JP
Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous bilateral atypical femoral fractures after alendronate therapy.
Zafeiris CP; Stathopoulos IP; Kourkoumelis G; Gkikas E; Lyritis GP
J Musculoskelet Neuronal Interact; 2012 Dec; 12(4):262-4. PubMed ID: 23196269
[No Abstract] [Full Text] [Related]
23. Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome.
Jones DG; Savage R; Highton J
BMJ; 2005 Jan; 330(7482):74. PubMed ID: 15637369
[No Abstract] [Full Text] [Related]
24. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
25. Hepatotoxicity induced by alendronate therapy.
Yanik B; Turkay C; Atalar H
Osteoporos Int; 2007 Jun; 18(6):829-31. PubMed ID: 17226065
[TBL] [Abstract][Full Text] [Related]
26. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
28. Nodular scleritis following alendronate therapy.
Tabbara KF
Ocul Immunol Inflamm; 2008; 16(3):99-101. PubMed ID: 18569796
[TBL] [Abstract][Full Text] [Related]
29. Considering competing risks . . . Not all black and white.
Cauley JA; Ensrud KE
Arch Intern Med; 2008 Apr; 168(8):793-5. PubMed ID: 18443252
[No Abstract] [Full Text] [Related]
30. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Yanik B; Bavbek N; Yanik T; Inegöl I; Kanbay M; Turgut FH; Uz E; Akçay A
Ren Fail; 2007; 29(4):471-6. PubMed ID: 17497471
[TBL] [Abstract][Full Text] [Related]
31. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
Binkley N; Ringe JD; Reed JI; Ljunggren O; Holick MF; Minne HW; Liu M; Lamotta A; West JA; Santora AC
Bone; 2009 Apr; 44(4):639-47. PubMed ID: 19185560
[TBL] [Abstract][Full Text] [Related]
32. [Damage to the respiratory tract due to aspirated alendronate].
Jungblut SA; Frickmann H; Achenbach HJ; Wagner TO
Pneumologie; 2007 Dec; 61(12):771-3. PubMed ID: 17929215
[TBL] [Abstract][Full Text] [Related]
33. [Alendronate-induced esophagitis. A report of 2 cases].
Girelli CM; Reguzzoni G; Rocca F
Recenti Prog Med; 1997 May; 88(5):223-5. PubMed ID: 9244956
[TBL] [Abstract][Full Text] [Related]
34. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
36. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock O; Boerst H; Thomasius FE; Degner C; Stephan-Oelkers M; Valentine SM; Felsenberg D
J Musculoskelet Neuronal Interact; 2007; 7(2):144-8. PubMed ID: 17627083
[TBL] [Abstract][Full Text] [Related]
37. Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis.
Gerster JH
J Rheumatol; 2004 Apr; 31(4):829-30. PubMed ID: 15095748
[No Abstract] [Full Text] [Related]
38. [Alendronate for the prevention and treatment of postmenopausal osteoporosis. A survey of a Cochrane review].
Eiken PA; Abrahamsen B
Ugeskr Laeger; 2009 Mar; 171(11):903-6. PubMed ID: 19278615
[No Abstract] [Full Text] [Related]
39. Zenker's diverticulitis secondary to alendronate ingestion: a rare cause of recurrent dysphagia.
Sharma R; DeCross AJ
Gastrointest Endosc; 2011 Feb; 73(2):368-70. PubMed ID: 21295647
[TBL] [Abstract][Full Text] [Related]
40. Multiple miliary osteoma cutis of the face after initiation of alendronate therapy for osteoporosis.
Riahi RR; Cohen PR
Skinmed; 2011; 9(4):258-9. PubMed ID: 21980713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
